title: Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study.
abstract: Stimulant medication is known to cause transient weight loss and slowing down of growth, but whether it delays physical maturation is unclear. We studied growth and bone age over the first 3 years of treatment in children with attention-deficit/hyperactivity disorder (patients) compared with healthy siblings (controls). Bone age was estimated blindly by two independent radiologists using Tanner and Whitehouse version 3. Dexamphetamine or methylphenidate was titrated and continued when clinically indicated. Forty out of 73 patients, together with 22 controls, completed the study. There were no significant growth differences between the two groups at baseline. Despite slower growth on treatment [5.1 cm/year, 95% confidence interval (CI): 4.7-5.5, vs. 6.3 cm/year, 95% CI: 5.7-6.8, P=0.002; and 2.7 kg/year, 95% CI: 2.1-3.3, vs. 4.4 kg/year, 95% CI: 3.5-5.3, P=0.005], the patients showed no significant maturational delay (RUS score: 49 U/year, 95% CI: 44-55, vs. 55 U/year, 95% CI: 47-63, P=0.27). A subgroup of patients underwent serial biochemistry and dual-energy X-ray absorptiometry, recording a significant reduction in fat (5.61±3.56-4.22±3.09 kg, P<0.001) and leptin (3.88±2.87-2.57±1.94 ng/ml, P=0.017). The pattern of change in height z-score over time was modified by the dose of medication (P for interaction=0.024). We found no medication effect on the rate of maturation, which was instead predicted by baseline leptin (P=0.035 controlling for age and sex).
authors.affiliation: aSydney Medical School Nepean, University of Sydney bDepartment of Medical Imaging, Nepean Blue Mountains Local Health District, Nepean Hospital, Penrith, New South Wales, Australia.
authors.forename: Alison S
authors.initials: AS
authors.lastname: Poulton
authors.forename: Quoc
authors.initials: Q
authors.lastname: Bui
authors.forename: Elaine
authors.initials: E
authors.lastname: Melzer
authors.forename: Richard
authors.initials: R
authors.lastname: Evans
mesh_terms: D015502:Absorptiometry, Photon; D050154:Adiposity / Q000187:drug effects; D000367:Age Factors; D000886:Anthropometry; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015415:Biomarkers / Q000097:blood; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects*; D016022:Case-Control Studies; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D002648:Child; D002657:Child Development / Q000187:drug effects*; D003913:Dextroamphetamine / Q000009:adverse effects*; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D020738:Leptin / Q000097:blood; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000697:Central Nervous System Stimulants; D020738:Leptin; D008774:Methylphenidate; D003913:Dextroamphetamine